Key result
Fatty pancreas in MAFLD is linked to ~2-fold higher rates of advanced fibrosis.
Why the study?
Is non-alcoholic fatty pancreatic disease associated with worsened metabolic and hepatic profiles in patients with metabolic-associated fatty liver disease?
Cross-Sectional (n=72)
Is non-alcoholic fatty pancreatic disease associated with worsened metabolic and hepatic profiles in patients with metabolic-associated fatty liver disease?
Absolute Event Rate: 15.9% vs 7.1%
p-value: p=0.003
The coexistence of non-alcoholic fatty pancreatic disease and metabolic-associated fatty liver disease is associated with worsened metabolic and hepatic profiles, highlighting the need for comprehensive metabolic assessment.
Background Metabolic-associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) are increasingly recognized as components of metabolic syndrome, sharing common risk factors and pathogenic mechanisms. Understanding their association can enhance early detection and management strategies. Our study aims to assess the association between MAFLD and NAFPD. Methods This cross-sectional study included 72 adult cases with sonographically confirmed MAFLD. All participants underwent clinical evaluation, laboratory testing (including glycemic and lipid profiles, liver and pancreatic enzymes), and imaging studies (abdominal ultrasound and computed tomography (CT) pancreas protocol). Fatty Liver Index (FLI) and NAFLD Fibrosis Score (NFS) were calculated for all cases. Based on CT findings, cases were categorized into normal pancreas ( n = 28) and fatty pancreas groups ( n = 44). Results Patients with fatty pancreas were significantly older (54 ± 10 vs. 39 ± 12 years, p < 0.001), had higher body mass index (BMI) (33.4 ± 4.52 vs. 30.06 ± 5.18, p = 0.005), and more frequent diabetes (70.5% vs. 7.1%, p = 0.0001) and hypertension (47.7% vs. 10.7%, p = 0.001) than those with normal pancreas. They also had higher triglycerides (195.45 ± 86.99 vs. 140.07 ± 63.55, p = 0.005), lower high-density lipoprotein (HDL) (38.25 ± 12.19 vs. 44.96 ± 8.73, p = 0.014), higher FLI scores (78 ± 15.15 vs. 60.14 ± 24.32, p < 0.001), and more advanced fibrosis (15.9% vs. 7.1%, p = 0.003). Conclusions NAFPD is associated with MAFLD and worsened metabolic and hepatic profiles. Their coexistence underscores the need for comprehensive metabolic assessment in affected cases.
No takes yet. Share an insight, caveat, or question.
Abdelmeged et al. (2026) conducted a cross-sectional in Metabolic associated fatty liver disease (MAFLD) (n=72). Fatty pancreas (NAFPD) vs. Normal pancreas was evaluated on Advanced fibrosis (p=0.003). Among patients with MAFLD, the presence of fatty pancreas was associated with significantly higher rates of diabetes (70.5% vs 7.1%) and advanced fibrosis (15.9% vs 7.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: